-
Tofacitnib Citrate
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Tofacitnib Citrate Rheumatoid arthritis Mumba -
Sugammadex Sodium
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Sugammadex Sodium Neuromuscular blockade Mumba -
Sacubitril Hemicalcium
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Sacubitril Hemicalcium Mumba -
Sofosbuvir
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Sofosbuvir HCV Mumba 32048 √ -
Ribociclib 1374639-75-4
Zita reAPI Indication Innovator Patent Expiry Date (The US) Ribociclib 1374639-75-4 HR-positive, HER2-negative Andvance ormetastaticbreast Cancers Novartis
PharmaceuticalsJun.27, 2028 -
Rivaroxaban
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Rivaroxaban Anticoagulant Mumba TDP -
Rosuvastatin Calcium
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Rosuvastatin Calcium Hypercholesterolemia Mumba/CEP 20705 √ CEP2015-240 -
Pitavastatin Calcium
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Pitavastatin Calcium Hypercholesterolemia Mumba -
Pregabalin
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Pregabalin Epilepsy/Neuralgia Mumba/EP 22223 √ CEP2016-141 -
Obeticholic Acid
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Obeticholic Acid Biliary cholangitis Mumba -
Niraparib 1038915-60-4
Zita reAPI Indication Innovator Patent Expiry Date (The US) Niraparib 1038915-60-4 Ovarian/Fallopian,chubhu/primary peritoneal cancer Tesaro Ndira 8, 2028 -
Ledipasvir Actone /PVP
Zita reAPI Indication Tsanangudzo US DMF EU DMF CEP Ledipasvir Actone /PVP HCV Mumba √
